Skip to main content

Opocrin S.p.A. becomes the main shareholdres of Omikron Italia S.r.l., a pharmaceutical company that develops innovative therapeutic solutions for vascular and ophthalmic pathologies. 

An initiative aimed at gradually responding to the therapeutic needs of vascular patients and those affected by major eye diseases.

Omikron Italia S.r.l. was born from the conviction that vascular, ophthalmic and metabolic pathologies require further development by searching innovative therapeutic solutions (drugs, medical devices, foods for special medical purposes, nutraceuticals).

Therefore, Omikron Italia S.r.l. works to develop new therapeutic solutions, acquires Marketing Authorization of commercial drug and the representation of products available worldwide.

Omikron Italia S.r.l. with its 16 years of experience in the pharma field, undertakes to annualy invest 15% of its turnover in Research & Development.

The company operates in the pharmaceutical sector and is presented as a partner of Specialists and Doctors of General Medicine to respond exhaustively to the therapeutic needs of vascular patients and those who are affected by major eye and metabolic diseases.

For Opocrin Group, this strengthens a business model vertically integrated in the production of heparin and heparinoids, guaranteeing the Group complete control of the quality of the product, starting from the mucosa to the active ingredient.